Sanofi R&D chief urges Western pharma to factor China’s growing innovation into pipelines

Sanofi’s newly appointed head of research and development said on Wednesday that Western pharmaceutical companies can no longer overlook China’s rapid progress in biopharma innovation.

He noted that Chinese firms are advancing new molecules and clinical capabilities at a pace that could reshape global drug pipelines, and that this shift should influence how Western companies source and prioritize candidates.

The comment suggests that future partnership models, investment decisions, and R&D strategies may need to incorporate Chinese research more directly to stay competitive.